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Psoriasis is a common skin disorder that aff  ects 
 2% of the worldwide population. Lesions are 
typically well-demarcated erythematous, scaly 
plaques. Histologically, there is marked epider-
mal hyperplasia (acanthosis) accompanied by 
parakeratosis (retention of keratinocyte nuclei 
in the stratum corneum) and a mixed dermal 
infi   ltrate, including CD4+ T cells, dendritic 
cells, macrophages, and mast cells. Neutro-
philic exudates are often seen (Munro micro-
abscesses) and CD8+ T cells are present in the 
epidermis. Dermal papillary blood vessels are 
dilated and tortuous, and there is increased ex-
pression of angiogenesis-associated genes (1).
The pathogenesis of psoriasis is unclear, 
but the eff  ectiveness of cyclosporine and other 
newer agents implicates an important role for 
T cells. No clear-cut autoantigens, however, 
have been described, and it is likely that the 
  innate immune system is also involved (2). Bac-
terial infections and physical trauma (Köebner’s 
phenomenon) often precede lesion formation 
and neutrophil accumulation in the dermis, 
and an infl  ux into the epidermis is observed in 
initial pre-pinpoint lesions (3). Plasmacytoid 
pre–dendritic cells initiate psoriasis in a xeno-
graft animal model (4), and other cells, includ-
ing dermal dendritic cells and NK T cells, have 
also been implicated (5, 6). Given their ability 
to link the innate and acquired immune systems, 
dysregulated cytokine production (elevated 
levels of TNF, IFN-γ, IL-1α, IL-1β, TGF-α, 
IL-6, and other cytokines in lesional skin) is 
postulated to establish chronic lesions by pro-
viding persistent proinfl  ammatory  signals  in 
the skin (7). Immune deviation from a Th1 to 
Th2 cytokine milieu can ameliorate disease, 
which also supports the cytokine hypothesis 
(8). Additionally, a novel family of IL-10–
  related cytokines consisting of IL-19, IL-20, 
and IL-24 has recently been associated with 
psoriasis, but their roles in disease pathogenesis 
are unclear (9).
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Aberrant cytokine expression has been proposed as an underlying cause of psoriasis, although 
it is unclear which cytokines play critical roles. Interleukin (IL)-23 is expressed in human 
psoriasis and may be a master regulator cytokine. Direct intradermal administration of IL-23 
in mouse skin, but not IL-12, initiates a tumor necrosis factor–dependent, but IL-17A–
independent, cascade of events resulting in erythema, mixed dermal infi  ltrate, and epi-
dermal hyperplasia associated with parakeratosis. IL-23 induced IL-19 and IL-24 expression 
in mouse skin, and both genes were also elevated in human psoriasis. IL-23–dependent 
epidermal hyperplasia was observed in IL-19−/− and IL-24−/− mice, but was inhibited in 
IL-20R2−/− mice. These data implicate IL-23 in the pathogenesis of psoriasis and support 
IL-20R2 as a novel therapeutic target.
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IL-23 is a recently described, IL-12–related heterodimeric 
cytokine (10). IL-23 and IL-12 both contain the IL-12p40 
subunit, which is paired with IL-23p19 and IL-12p35, 
  respectively. The heterodimeric receptors for IL-23 and IL-12 
consist of IL-23R paired with IL-12Rβ1 and IL-12Rβ2 
paired with IL-12Rβ1, respectively (11, 12). IL-23 has a 
dominant role over IL-12 in driving animal models of chronic 
autoimmune disease (13, 14), and IL-23 transgenic mice have 
systemic infl  ammation involving multiple organs, including 
the skin (15, 16). IL-23 is produced by dendritic cells and 
macrophages in response to bacteria, including Bordetella 
  pertussis (17), Mycobacterium tuberculosis (18), Streptococcus pyogenes 
(19), and Klebsiella pneumoniae (20). IL-23 gene expression is 
increased in psoriatic lesions compared with uninvolved skin 
(21), but downstream consequences of IL-23 dysregulation 
are unclear. We demonstrate that intradermal delivery of 
IL-23 protein in mice results in acute skin histopathology 
that shares many features of psoriasis. We also show a role for 
the IL-19 family of cytokines, via the shared receptor 
IL-20R2, in IL-23–dependent epidermal hyperplasia, sup-
porting IL-20R2 as a novel therapeutic target.
RESULTS
Elevated IL-23 is associated with human psoriasis
IL-23p19 mRNA expression was increased in lesional psori-
atic skin compared with nonlesional skin from psoriatic and 
normal donors (Fig. 1 A, left), in agreement with a previ-
ous report (21). Similar results were observed for IL-12p40, 
Figure 1.  IL-23 is associated with human psoriasis and drives epi-
dermal hyperplasia in mice. Expression of IL-23p19, IL-12p40, and IL-
12p35 mRNA in normal, nonlesional (NL), and lesional (L) human psoriatic 
skin. Bar represents median (A). Representative photographs (B) of 129SvEv 
mice at day 4 treated with daily injections of saline (left) or 1 μg IL-23 
(right). Representative frozen sections stained for CD31. Samples were 
taken at day 4 from 129SvEv mice treated daily with saline (top) or 1 μg 
IL-23 (bottom). Red arrows indicate CD31 staining in the dermal papillary. 
Bar, 100 μm (C). Representative histological sections at day 4 of littermate 
wild-type C57BL/6 mice treated daily with saline (left) or 1 μg IL-23 (middle), 
and IL-23R−/− mice treated daily with 1 μg IL-23 (right). Red arrows 
indicate parakeratosis. Green arrows indicate neutrophilic exudates. Bar, 
100 μm (D). Epidermal thickness was measured in 129SvEv mice treated 
daily with saline (○) or 1 μg IL-23 (●). Data was pooled together from 
six independent experiments performed in quadruplicate. Mean ± SD is 
shown. *, P < 0.001 (E). Epidermal thickness was measured at day 4 in 
129SvEv mice treated daily with saline, 1 μg IL-23, 1 μg IL-12, or 1 μg 
TNF. Data was pooled together from two independent experiments (F).JEM VOL. 203, November 27, 2006  2579 
ARTICLE
including increased expression in nonlesional psoriatic skin 
compared with normal controls (Fig. 1 A, middle). In con-
trast, IL-12p35 expression was not increased but actually de-
creased in lesional psoriatic skin compared with nonlesional 
and normal skin (Fig. 1 A, right).
IL-23 drives infl  ammation and epidermal hyperplasia 
in mouse skin
Because IL-23 is elevated in human psoriasis, we injected 
IL-23 protein intradermally into mice to explore the down-
stream consequences of aberrant cutaneous IL-23 exposure. 
Wild-type mice treated daily with IL-23, but not saline, de-
veloped visually apparent erythema and induration (Fig. 1 B) 
and associated prominent dermal papillary blood vessels (Fig. 
1 C). Induration was apparent by day 2 and persisted to day 7. 
Erythema was also apparent at day 2 but began to recede at 
day 5. Histological evaluation of IL-23–treated skin showed 
epidermal (and follicular) hyperplasia accompanied by para-
keratosis at day 4 (Fig. 1 D, middle, red arrows). No rete 
ridges were observed, although hair follicles cut in the appro-
priate plane may falsely suggest otherwise. Focal neutrophilic 
exudates, reminiscent of Munro microabscesses, were often 
observed (Fig. 1 D, middle, green arrows). Markedly less 
parakeratosis and fewer focal neutrophilic exudates were ob-
served by day 7 (unpublished data).
The specifi  city of this observation was confi  rmed using 
IL-23R–defi  cient mice (Fig. S1, available at http://www.
jem.org/cgi/content/full/jem.20060244/DC1), which did 
not respond to intradermal IL-23 treatment (Fig. 1 D, right). 
IL-23–induced epidermal thickening was maximal by day 4 
and began to decrease by day 7 (Fig. 1 E). IL-12 treatment, 
in comparison, did not induce signifi  cant changes in epider-
mal thickness. No changes in epidermal thickness were ob-
served with TNF treatment either (Fig. 1 F), in agreement 
with a previous report (22). Bioactivity of these cytokines 
was confi  rmed by examining expression of IL-12–dependent 
(IFN-γ, CXCL9, and CXCL10) and TNF-dependent 
(VCAM-1) genes in skin samples (Fig. S2). Immunohisto-
chemical analysis demonstrated a mixed dermal infi  ltrate 
consisting of CD4+ T cells, CD11c+ dendritic cells, F4/80+ 
macrophages, and neutrophils that began 1 d after IL-23 
treatment and was markedly increased by day 4 (Fig. S3). No 
CD8+ T cells or increased numbers of mast cells were de-
tected at either time point, in contrast to psoriasis (unpub-
lished data). Aside from the obvious local changes in skin 
appearance, the IL-23 treatment regimen was well tolerated 
because the mice appeared healthy and did not lose weight 
during the course of the experiment. Serum cytokine levels, 
including GM-CSF, IL-1β, IL-2, IL-4, IL-5, IL-6, TNF, and 
IFN-γ, remained unchanged compared with saline-treated 
controls (unpublished data).
Epidermal thickening associated with IL-23 exposure was 
examined in detail using transmission electron microscopy. 
Hyperplastic skin was selected from animals without histo-
pathologic evidence of suppurative dermatitis (day 4) for the 
purpose of defi  ning ultrastructural features of the model in 
the absence of cellular infi  ltrates. Acanthosis (increased thick-
ness of the stratum spinosum) was a predominant feature and 
accounted for the majority of the epidermal thickening and 
was characterized by spinous cell hyperplasia, hypertrophy, 
and spongiosis (intercellular edema) (Fig. 2 A). Spinous cells, 
although enlarged, maintained normal cytoplasmic contents 
and membrane structure. The granular cell layer (stratum 
granulosum) was more prominent in IL-23–treated treated 
skin when compared with untreated control skin. However, 
it was still very sparse, even in severely thickened skin, and 
often showed retained “end-stage” nuclei (i.e., nuclei with 
condensed and marginated chromatin). Nuclear fragmenta-
tion was not observed within this layer. The stratum corneum 
was characterized by altering areas of hyperparakeratosis 
Figure 2.  IL-23–stimulated epidermal thickening is due to keratino-
cyte hyperplasia in the spinous layer and altered granular layer 
differentiation. Low magnifi  cation (bar, 8.4 μm) of skin illustrating the 
major ultrastructural features of IL-23–induced epidermal hyperplasia, 
including hypertrophy and hyperplasia of the spinous layer, with spon-
giosis and retained nuclei as well as compacted keratin fi  laments in the 
keratin layer (A). Transmission electron photomicrograph of skin from an 
IL-23–treated mouse showing retained nuclei (single arrows) within the 
stratum corneum. Note the division between the cornifi  ed and granular 
layers (double arrow). Bar, 9.7 μm (B).2580  ROLE OF IL-23 AND IL-20R2 IN PSORIASIS | Chan et al.
(cells with retained epithelioid nuclei, keratohyalin granules, 
and compacted keratin fi  laments) and orthohyperkeratosis 
(Fig. 2 B). These results are discussed in the context of 
  psoriasis keratinocyte biology in the Discussion. Additional 
transmission electron microscopy pictures are available at 
http://www.jem.org/cgi/content/full/jem.20060244/DC1.
IL-17A is not required for IL-23–dependent 
epidermal hyperplasia
IL-17A is a proinfl  ammatory cytokine that lies downstream 
of IL-23 in the pathogenesis of experimental autoimmune 
encephalomyelitis and whose presence is correlated with the 
progression of collagen-induced arthritis (13, 23). Human 
psoriatic skin has elevated IL-17A gene expression in lesions 
relative to nonlesional skin and normal controls (Fig. 3 A). 
IL-17A mRNA expression was increased in IL-23–treated 
mouse skin at day 1 and remained elevated at day 4 (Fig. 3 C). 
We used a blocking monoclonal antibody to IL-17A to de-
termine whether IL-17A is required for IL-23–dependent 
epidermal thickening. Anti–IL-17A did not inhibit IL-23–
stimulated acanthosis (Fig. 3 E), nor did it aff  ect IL-23–
  dependent erythema, induration, and parakeratosis (unpublished 
data). Anti–IL-17A treatment inhibited IL-23–stimulated G-
CSF (Fig. 3 G) and MMP-13 expression (unpublished data), 
genes previously shown to be IL-17A regulated (24, 25). This 
anti–IL-17A antibody is effi     cacious at inhibiting experi-
mental autoimmune encephalomyelitis, where IL-17A expressed 
in the central nervous system is a key pathogenic factor that 
contributes to paralysis (26), and also in inhibiting collagen-
induced joint infl  ammation models, where IL-17A is a key 
pathogenic factor driving cartilage and bone destruction 
(unpublished data). Intradermal IL-17A delivery caused signif-
icant keratinocyte hypertrophy, but minimal if any hyperplasia 
by day 4 (unpublished data).
Role of TNF in IL-23–dependent epidermal hyperplasia
TNF is a validated target for various infl  ammatory diseases, 
including psoriasis (27, 28). TNF mRNA was elevated in 
human psoriatic skin relative to normal controls (Fig. 3 B) and 
was also induced in mouse skin by intradermal IL-23 treatment 
at day 1, but not at day 4 (Fig. 3 D). TNF protein was also 
detected by ELISA in IL-23–treated skin (unpublished data). 
We used a blocking monoclonal antibody to TNF to deter-
mine whether TNF is involved in IL-23–dependent epidermal 
thickening. In contrast to anti–IL-17A, anti-TNF treatment 
partially inhibited IL-23–dependent acanthosis (Fig. 3 F), and 
the degree of erythema and induration was decreased.
IL-23 indirectly stimulates keratinocyte proliferation
Immunohistochemical analysis of IL-23–treated skin at day 1 
showed increased Ki67+ cells in the epidermis, suggesting that 
keratinocytes had received an IL-23–stimulated proliferative 
signal by day 1 (Fig. 4 A). This observation was confi  rmed by 
increased keratin 16 (K16) gene expression, which is associated 
with keratinocyte hyperplasia in psoriasis (29). Elevated K16 
was evident at day 1, before changes in epidermal thickness, 
and was further increased at day 4 (Fig. 4 B). Increased expres-
sion of K16 was induced by IL-23, but not IL-12 or TNF 
Figure 3.  IL-17A is not required for IL-23–dependent epidermal 
hyperplasia. Expression of IL-17A (A) or TNF (B) mRNA in human psori-
atic skin. Expression of IL-17A (C) or TNF (D) mRNA in mice treated daily 
with saline (open bars) or 1 μg IL-23 (fi  lled bars). Data are mean ± SEM 
of three independent experiments using 129SvEv, C57BL/6, or B6 × 129 
mice, where mRNA was pooled together from four mice per group. 
*, P < 0.05. Epidermal thickness at day 4 in 129SvEv mice treated daily 
with saline or 1 μg IL-23 in the presence of anti–IL-17A (E) or anti-TNF (F) 
blocking monoclonal antibody or isotype control. Sum of two indepen-
dent experiments for each antibody is shown. Expression of G-CSF (G) at 
day 4 in 129SvEv mice (n = 4, mRNA was pooled together) treated daily 
with saline or IL-23 in the presence of blocking anti–IL-17A monoclonal 
antibody (fi  lled bars) or isotype control (open bars). One of two represen-
tative experiments is shown.JEM VOL. 203, November 27, 2006  2581 
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(Fig. 4 C). Gene expression analysis of skin samples at day 1 
suggested that the eff  ects of IL-23 treatment on epidermal hy-
perproliferation were not due to increased gene expression of 
a panel of keratinocyte growth factors (Fig. 4 D). Furthermore, 
in vitro assays indicated that IL-23 did not have a direct eff  ect 
on keratinocyte proliferation (Fig. 4 E).
IL-19 family members are stimulated by IL-23 
and expressed in human psoriatic skin
Because IL-23 did not stimulate the expression of any 
growth factors tested at day 1 (a time point before visual 
epidermal thickening, but after a keratinocyte proliferative 
signal had been received based on Ki67 staining and K16 
expression), we examined the novel IL-19 family of cy-
tokines, which consists of IL-19, IL-20, and IL-24. These 
cytokines all bind the heterodimeric receptor IL-20R1/IL-
20R2. IL-20 and IL-24 can also bind IL-22R1/IL-20R2 
(30). These receptors are highly expressed in epithelial cells, 
including keratinocytes (31, 32), and are all elevated in hu-
man psoriatic skin (9), suggesting a possible role in disease 
pathology. IL-23 delivery to mouse skin elevated IL-19 and 
IL-24, but not IL-20, gene expression (Fig. 5, left). IL-23 
did not increase IL-20R1, IL-20R2, or IL-22R1 gene ex-
pression in mouse skin (unpublished data). IL-19, IL-20, 
and IL-24 mRNA was also increased in human psoriatic 
skin relative to normal controls (Fig. 5, right). IL-20R1 
and IL-22R1 were elevated in psoriatic skin compared with 
normal controls, whereas no signifi  cant changes were ob-
served for IL-20R2 (Fig. S4, available at http://www.jem.
org/cgi/content/full/jem.20060244/DC1).
Role of IL-20R2 in IL-23–dependent epidermal hyperplasia
IL-23 was delivered into the skin of IL-20R2−/− mice 
(Fig. S5, available at http://www.jem.org/cgi/content/full/
jem.20060244/DC1) to simultaneously examine the role of 
Figure 4.  IL-23 stimulates keratinocyte proliferation in mice. 
  Representative immunohistochemical staining for Ki67 in mice at day 1 (A) 
after treatment with saline (top) or 1 μg IL-23 (bottom). Bar, 20 μm. 
Expression of K16 mRNA (B) in mice treated daily with saline (open bars) 
or 1 μg IL-23 (fi  lled bars). Data are mean ± SEM of three independent 
experiments using 129SvEv, C57BL/6, or B6 × 129 mice, where mRNA 
was pooled together from four mice per group. *, P < 0.05. K16 mRNA 
expression in mice at day 4 treated daily with saline, 1 μg IL-23, 1 μg 
IL-12, or 1 μg TNF. Data are mean ± STD, n = 4. One of two representa-
tive experiments is shown (C). mRNA expression at day 1 for a panel of 
keratinocyte growth factors (D) in mice treated with saline (open bars) or 
IL-23 (fi  lled bars). Data are mean ± SEM of three independent experi-
ments using 129SvEv, C57BL/6, or B6 × 129 mice, where mRNA was 
pooled together from four mice per group. Keratinocyte proliferation 
assay (E) in which normal human keratinocytes were treated in triplicate 
with vehicle or IL-23 (1, 10, or 100 ng/ml). 10 ng/ml KGF was used as a 
positive control. One of three representative experiments is shown.
Figure 5.  IL-19 family members are expressed in human psoriatic skin 
and stimulated by IL-23 in mouse skin. IL-19 (A), IL-20 (B), and IL-24 (C) 
mRNA expression was measured in mice (left) treated daily with saline (open 
bars) or 1 μg IL-23 (fi  lled bars), and in human psoriatic skin (right). Mouse 
data are mean ± SEM of three independent experiments using 129SvEv, 
C57BL/6, or B6 × 129 mice, where mRNA was pooled together from four 
mice per group. *, P < 0.05. Bar represents median for human samples.2582  ROLE OF IL-23 AND IL-20R2 IN PSORIASIS | Chan et al.
all three IL-19 family cytokines. Epidermal thickening was 
signifi  cantly inhibited in IL-23–treated IL-20R2−/− mice 
compared with IL-23–treated wild-type controls (Fig. 6 A), 
despite the induction of IL-19 and IL-24 gene expression 
(Fig. 6 B). IL-23 was delivered into the skin of IL-19−/− and 
IL-24−/− mice (Fig. S6 and S7, respectively) to determine if 
IL-19 or IL-24 was required for IL-23–dependent epidermal 
hyperplasia. IL-23–stimulated epidermal thickening was 
  observed in both IL-19−/− and IL-24−/− mice (Fig. 6 A). 
These data suggest that these cytokines are redundant in 
function because IL-24 and IL-19 gene expression was in-
duced in IL-19−/− and IL-24−/− mice, respectively (Fig. 6, 
C and D). IL-20 gene expression was not signifi  cantly al-
tered by IL-23 in skin from either IL-19−/− or IL-24−/− 
mice compared with wild-type controls (unpublished data). 
Importantly, in vitro stimulation of keratinocytes with 
  increasing quantities of IL-19, IL-20, or IL-24 failed to stim-
ulate proliferation, suggesting that IL-20R2 ligands are 
  required but not suffi   cient for IL-23–stimulated epidermal 
hyperplasia (unpublished data).
Impaired leukocyte recruitment in IL-23–treated 
IL-20R2−/− mice
We performed immunohistochemical analysis on IL-23–
treated IL-20R2−/− skin to determine whether impaired 
  signaling through IL-20R2 aff  ected the cellular composition 
of the dermal infi  ltrate. Although epidermal thickening was 
not apparent in IL-23–treated IL-20R2−/− mice, there were 
elevated numbers of CD4+ T cells and CD11c+ dendritic 
cells compared with saline-treated control mice, which was 
similar to IL-23–treated wild-type mice (Fig. 6, E and F, 
  respectively). In contrast, there were reduced numbers of 
dermal F4/80+ macrophages and neutrophils in IL-20R2−/− 
mice (Fig. 6, G and H). Table I summarizes the diff  erences 
between human psoriasis and wild-type or IL-20R2−/− mice 
in their responses to intradermal IL-23 treatment.
DISCUSSION
Because IL-23p19 and IL-12p40 gene expression was elevated 
in lesional psoriatic skin compared with nonlesional psoriatic 
skin and normal controls, we tested the hypothesis that IL-23 
was involved in disease pathogenesis by injecting IL-23 intra-
dermally into mice. IL-23 induced changes in mouse skin that 
share many features with human psoriasis, as summarized in 
Table I. The most striking similarity to psoriasis microscopi-
cally was the acanthosis (epithelial hyperplasia) and parakera-
tosis (keratinocyte nuclei in the stratum corneum).
Histological analysis of psoriatic skin reveals the absence 
of the normal granular layer where normal keratinocyte dif-
ferentiation starts to give rise to a highly cross-linked, lipid-
rich anuclear structure that provides the fi  rst barrier to the 
environment (i.e., stratum corneum). In normal skin, the 
granular layer is defi  ned by numerous keratinocyte nuclei 
undergoing condensation and disintegration. Psoriatic skin, 
however, has little to no keratinocyte nuclei disintegration, 
which ultimately results in a modifi  ed stratum corneum with 
retained keratinocyte nuclei (parakeratosis). One diff  erence 
between the acute IL-23–induced skin hyperplasia response 
and the chronic psoriatic lesional skin, however, is that a 
modifi  ed granular layer is present. IL-23–stimulated granular 
layer keratinocytes have nuclei condensation but no evidence 
of nuclei disintegration. This gives rise to parakeratosis, simi-
lar to psoriasis, by a slightly diff  erent mechanism than ob-
served in psoriasis. Whether this is due to the IL-23–stimulated 
hyperplasia being an acute self-limiting condition versus the 
Figure 6.  Role of IL-20R2 in IL-23–dependent epidermal hyperplasia. 
Epidermal thickness was measured at day 4 in wild-type, IL-20R2−/−, 
IL-19−/−, or IL-24−/− mice treated daily with saline (open symbols) or 
1 μg IL-23 (fi  lled symbols). Data from different wild-type strains were 
pooled together because no differences in IL-23–stimulated epidermal 
thickening were observed. Data are the aggregate of seven independent 
experiments (each strain of mouse was used in at least two separate 
experiments) (A). IL-19 and IL-24 gene expression in IL-20R2−/− mice at 
day 4 (B). IL-24 gene expression in IL-19−/− mice at day 4 (C). IL-19 gene 
expression in IL-24−/− mice at day 4 (D). Data are representative of two 
independent experiments where mRNA (n = 4) was pooled together. 
Representative immunohistochemical staining for CD4+ T cells (E), CD11c+ 
dendritic cells (F), F4/80+ macrophages (G), and neutrophils (H) at day 
4 in IL-20R2−/− mice treated daily with saline (left) or 1 μg IL-23 (middle), 
or littermate wild-type mice at day 4 treated daily with 1 μg IL-23 (right). 
Bar, 100 μm.JEM VOL. 203, November 27, 2006  2583 
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chronic nature of psoriatic lesions is under investigation. 
  Reversible edema in the epidermis (spongiosis) was also ob-
served in the acute model, which is not commonly seen in 
chronic psoriatic skin lesions. A rare disease, granular para-
keratosis, is characterized by parakeratosis but in combination 
with a granular layer. IL-23 may also play a role in this disease 
due to the similarities between it and our observations in this 
mouse model.
An IL-12p40 antagonist that blocks IL-23 and IL-12p70 
simultaneously was successful in a phase I psoriasis clinical 
trial (33), and IL-23p19, but not IL-12p35, gene expression 
was associated with human psoriasis (21). These data plus the 
observation that intradermal injections of IL-12 did not cause 
psoriasiform lesions in mice are consistent with IL-23 being 
the relevant target of anti–IL-12p40 therapy in psoriasis. It is 
noteworthy that IL-12 treatment did not induce psoriasiform 
lesions despite enhanced IFN-γ expression because human 
psoriatic lesions have a distinct signature of IFN-γ–regulated 
genes (34). This raises the possibility that IL-23 (dys)regulation 
may trigger psoriatic lesion formation and that IFN-γ–
  dependent processes may contribute to the chronicity of 
  disease. This notion is consistent with IL-23 production early 
in an innate immune response to bacteria (17–20) that may 
initiate psoriatic lesions and with the multigenic nature of this 
disease (35).
IL-23 is a potent regulator of memory T cell develop-
ment and/or expansion that is skewed to IL-17A secretion 
(36), and IL-23 has been implicated as a key disease driver in 
autoimmune disease models (13, 23). The human psoriatic 
data demonstrate that IL-17A gene expression is also associ-
ated with disease. Intradermal IL-23 injections stimulated 
  elevated IL-17A expression; however, pretreatment with an 
antagonistic antibody did not ameliorate psoriasiform lesion 
formation. These data and the observation that direct IL-17A 
delivery has minimal eff  ect on epidermal hyperplasia suggest 
that IL-17A, although downstream of IL-23 and associated 
with human psoriasis, is not required for disease pathogenesis. 
It is possible that IL-17F, whose expression is also skewed by 
IL-23 during memory T cell development (36) and is driven 
by IL-23 in this model (unpublished data), may compensate 
in some way for IL-17A because they both can bind IL-
17RC (37). Interestingly, psoriatic patients are relatively re-
sistant to cutaneous infections (38). IL-17A and IL-17F may 
play key roles in host defense to cutaneous infections because 
they stimulate neutrophil recruitment (39, 40), and IL-17A 
directly stimulates the anti-microbial gene β-defensin 2 in 
epithelial cells (41).
IL-23 stimulates macrophage TNF production (14) and 
IL-23p19 transgenic mice have elevated serum TNF levels 
(16). Neutralizing TNF partially inhibited epidermal hy-
perplasia induced by IL-23 in our study. This observation is 
consistent with the effi   cacy of anti-TNF–directed therapies 
in psoriasis (27, 28). TNF inhibition breaks the self-sustaining 
nature of psoriatic lesions by rapidly down-regulating 
  several proinfl   ammatory genes, including IL-23p19 and 
IL-19 (42). TNF alone, however, was not sufficient to 
  induce epidermal hyperplasia, indicating that IL-23 stimu-
lates other signaling pathways that synergize with TNF for 
disease pathogenesis.
The physiologic functions of the structurally related cy-
tokines IL-19, IL-20, and IL-24 appear to be quite diverse 
despite their shared receptor profi  le. IL-19 may be involved 
Table I.  Comparison of clinical and histological features of human psoriasis with IL-23–treated wild-type and IL-20R2−/− mouse skin
Human psoriasis IL-23–treated wild-type skin     IL-23–treated IL-20R2−/− skin
Clinical 
Erythematous yes yes minimal
Well-demarcated from symptomless skin yes no n/a
White-silvery scale yes no, although small areas of fl  aky skin no, no evidence of fl  aky skin
Histological
Acanthosis yes yes signifi  cantly reduced
Granular layer no yes, but no evidence of nuclei disintegration no
Parakeratosis yes yes no
Elongation of rete ridges yes no n/a
Follicular hyperplasia no yes no
Epidermal spongiosis no yes no
Intracorneal pustules (Munro microabscesses) yes yes no
Recruitment to dermis of:
CD4+ lymphocytes yes yes yes
Dendritic cells yes yes yes
Macrophages yes yes reduced
Neutrophils yes yes no
Mast cells yes no n/a
CD8+ cells in epidermis yes no n/a
Prominent dermal papillary blood vessels yes yes no2584  ROLE OF IL-23 AND IL-20R2 IN PSORIASIS | Chan et al.
in the induction of Th2 responses (43). IL-20 appears to play 
a key role in skin biology because IL-20 transgenic mice 
have aberrant epidermal diff   erentiation with no immune 
cell infi  ltrates (32). Adenoviral delivery of IL-24 (MDA-7/
mob-5/c49a) induces apoptosis in tumor cells (44), and 
IL-24 gene expression is increased during wound healing 
in the rat (45). The common link between IL-19, IL-20, 
and IL-24 is their use of heterodimeric receptors that share 
the IL-20R2 subunit: IL-20R1/IL-20R2 heterodimer and 
IL-22R1/IL-20R2 heterodimer (30). These receptors are 
primarily expressed in epithelial cells such as keratinocytes 
(31, 32) and are elevated in human psoriatic lesions (9, 32). 
Our human psoriatic data confi  rm that IL-20R1 and IL-
22R2 are increased in psoriatic skin, although we did not 
detect a statistically signifi  cant increase in IL-20R2 mRNA 
compared with normal skin. Administration of IL-23 to IL-
20R2−/− mice, but not IL-19−/− or IL-24−/− mice, resulted 
in signifi  cantly decreased acanthosis and parakeratosis. This 
suggests that either IL-19 or IL-24 may be suffi   cient to me-
diate epidermal hyperplasia via IL-20R2–containing recep-
tors, although it is unclear whether these cytokines directly 
stimulate keratinocyte proliferation or alter the keratinocyte 
diff  erentiation program.
Interestingly, cutaneous IL-23 exposure also drives high-
level expression of IL-22, a cytokine structurally related to 
IL-19, IL-20, and IL-24 (unpublished data). IL-22 binds the 
heterodimeric receptor IL-22R1/IL-10RB, but it does not 
use IL-20R2. IL-22 activation of keratinocytes stimulates a 
variety of antimicrobial activities, such as psoriasin (S100A7), 
calgranulin A (S100A8), calgranulin B (S100A9), β-defensin 2, 
and β-defensin 3 (46–48). Therefore, cutaneous IL-23 ex-
pression in psoriatic skin drives both IL-22–dependent and 
IL-17A/IL-17F–dependent antimicrobial responses that pro-
tect the host.
 The cellular mechanisms by which IL-23 drives IL-
20R2–dependent epidermal hyperplasia and psoriasiform le-
sions remain to be investigated. Analysis of the infl  ammatory 
cell infi  ltrate in IL-23–treated IL-20R2−/− mice revealed de-
creased numbers of neutrophils and F4/80+ macrophages in 
the dermis, suggesting that these recruited cells may contribute 
to the lesion development in our model. In support of this 
possibility, neutrophil depletion inhibits acanthosis in the 
fsn/fsn mouse, which spontaneously develops fl  aky skin (49). 
Infi  ltrating myeloid cells can produce several factors associ-
ated with psoriasis, including iNOS, IL-19, MMP-12, and 
IL-23 (42).
T cells, monocytes, and NK cells express IL-23R (11), 
which raises the possibility that IL-23 may act directly on 
these cells to produce IL-19 and IL-24. Published data show 
that the major hematopoietic sources of IL-19 and IL-24 are 
monocytes and monocytes and T cells, respectively (50). IL-23–
treated bone marrow macrophages do not express IL-19, 
IL-20, or IL-24 (unpublished data), suggesting that IL-19 and 
IL-24 expression may be indirectly stimulated by IL-23. This 
notion is supported by our data that keratinocytes do not re-
spond to IL-23 and that IL-19 is expressed by keratinocytes 
in psoriatic lesions (9). TNF may be important here as IL-23 
stimulates TNF expression in macrophages (14) and TNF di-
rectly stimulates IL-19 expression in normal human epider-
mal keratinocytes (unpublished data).
In summary, our data propose a molecular mechanism by 
which IL-23 dysregulation is one of the causative factors in 
psoriasis pathogenesis. Dysregulated cutaneous IL-23 pro-
duction sets into motion several independent pathways. IL-23 
contributes to the antimicrobial nature of psoriatic lesions by 
stimulating IL-17A (and IL-17F) and neutrophil recruitment. 
In parallel, IL-23 stimulates IL-19 and IL-24, which may 
  directly act on keratinocytes in a TNF-regulated manner re-
sulting in epidermal hyperplasia and/or altered keratinocyte 
diff  erentiation. These functionally diff  erent arms suggest that 
IL-23 may have evolved as a “response to danger” cytokine 
invoking the body to protect itself by rapidly mobilizing anti-
microbial components and instructing the epidermis to pro-
liferate to provide additional protection from the environment. 
Given that IL-23–dependent epidermal hyperplasia was in-
hibited in IL-20R2−/− mice, targeting IL-20R2 and/or its 
associated receptors may be a novel therapeutic strategy for 
the treatment of this disease.
MATERIALS AND METHODS
Human skin specimens. Psoriasis patients (n = 45) and normal volunteers 
(n = 30) consented under a protocol approved by the Stanford Panel on 
Human Subjects. Psoriasis patients needed to have a Psoriasis Area Severity 
Index of at least 8 and a typical lesion at least 1 cm in size suitable for biopsy. 
The target lesion and the surrounding 5-cm area could not have been treated 
with any medicated topical formulation for at least 2 wk before obtaining 
the biopsy. Patients treated with systemic immunosuppressives including 
corticosteroids were excluded. One 4-mm biopsy from a lesional and an 
  adjacent nonlesional site was collected from psoriatic patients. One 4-mm 
biopsy was obtained from each normal volunteer. Specimens were fl  ash 
  frozen in liquid nitrogen.
Reagents and antibodies. Generation of IL-23R−/−, IL-20R2−/−, IL-
19−/−, and IL-24−/− mice are described in Online supplemented material. 
Recombinant human and murine IL-23 have been described (10). Recom-
binant murine IL-12 was generated using approaches described previously 
(10). Murine TNF and human keratinocyte growth factor 1 (KGF) were 
purchased (PeproTech). Rat anti–IL-17A (JL7.1D10) (26), rat anti-TNF 
(MP6-XT22) (51), and isotype control antibody (25D2) were purifi  ed from 
hybridoma culture supernatants. Rat anti-Ki67 (TEC-3; DakoCytomation), 
rat anti-neutrophils (7/4; Serotec), rat anti-CD4 (L3T4; BD Biosciences), rat 
anti-F4/80 (A3-1; Serotec), hamster anti-CD11c (HL3; BD Biosciences), 
and rat anti-CD31 (MEC 13.3; BD Biosciences) were purchased.
IL-23–dependent skin infl  ammation model. All animal protocols were 
approved by DNAX/Schering-Plough Biopharma’s Institutional Animal 
Care and Use Committee. Hair was removed from the back of mice with 
electric clippers and a cream depilatory (Nair). 3 d later, mice were injected 
intradermally with IL-23, vehicle control, or other cytokines (IL-12 or 
TNF) in two locations on either side of the back for a total of 1 μg protein 
per mouse using a 29.5-gauge needle. Sterile saline was used as a vehicle 
control. Injections were performed daily until mice were killed as per the 
objective of the experiment. For antibody blocking studies, mice were 
treated subcutaneously with 0.2–1.0 mg anti–IL-17A, anti-TNF, or isotype 
control 2 d before the fi  rst cytokine injection. Mice were killed using carbon 
dioxide and blood was collected by cardiac puncture. Skin samples were re-
moved from the prepared area, keeping at least 5 mm away from the hair JEM VOL. 203, November 27, 2006  2585 
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boundary. Skin samples were frozen directly in liquid nitrogen for mRNA 
extraction, fi  xed in 10% neutral buff  ered formalin for histology, or embedded 
and frozen in OCT for immunohistochemistry.
Electron microscopy. Skin samples were fi  xed in a solution containing 
2.5% glutaraldehyde and 2% formaldehyde with 0.12 M sodium cacodylate 
followed by secondary fi  xation in buff  ered 1% OsO4. The samples were 
then dehydrated and embedded in epoxy resin by standard methods. Thin 
sections were stained with 5% uranyl acetate in 50% methanol and 1% aque-
ous lead citrate, and images were captured using an electron microscope 
(CM10; Philips).
RNA extraction and real-time quantitative PCR. RNA isolation was 
performed by standard techniques, and gene expression was calculated using 
the ∆-∆Ct method (using the mean cycle threshold value for ubiquitin and the 
gene of interest for each sample. The equation 1.8e (Ct ubiquitin − Ct gene 
of interest) × 104 was used to obtain the normalized values.
Histology and immunohistochemistry. Skin sections were stained with 
hematoxylin and eosin, and epidermal thickness was determined by measur-
ing the average interfollicular distance from the basal lamina to the bottom 
of the stratum corneum in a blinded manner. Similar results were obtained 
for wild-type mice on 129SvEv, C57BL/6, or mixed B6 × 129 genetic 
backgrounds. For immunohistochemistry, 8-μm sections were fi  xed with 
75% acetone/25% ethanol. Endogenous peroxidase was quenched with Per-
oxidase Blocking Reagent (DakoCytomation) and endogenous biotin was 
blocked with SP-2001 (Vector Laboratories). Primary antibodies were incu-
bated for 30 min at room temperature and visualized using V  E  C  T  A  S  T  A  I  N   
elite ABC kit (Vector Laboratories). Positive staining developed as a brown 
reaction precipitate.
In vitro keratinocyte proliferation assay. In vitro keratinocyte pro-
liferation assays were performed as described previously (52), with minor 
modifi  cation. Normal human epidermal keratinocytes (Cambrex) were seeded 
at 2,000/well in a 24-well plate in keratinocyte basal medium (Cambrex) sup-
plemented with hydrocortisone (Cambrex) and 5 μg/ml human recombinant 
insulin (Roche Diagnostics). During seeding, cells were treated with vehicle 
control, 1–100 ng/ml human IL-23, or 10 ng/ml KGF as a control. After 6 d, 
cells were washed and incubated with 0.2% crystal violet (Sigma-Aldrich). 
Cells were lysed with 1% SDS and absorbance was read at 565 nm. The total 
number of cells per well was determined by reference to a standard curve. All 
conditions were performed in triplicate.
Statistical analyses. Human data was analyzed by Kruskal-Wallis with 
Dunn’s Multiple Comparison after test. One-way or two-way ANOVA 
with Bonferroni after test were used where appropriate. P < 0.05 was con-
sidered to be statistically signifi  cant.
Online supplemented material. Fig. S1 is the gene deletion strategy for 
the IL-23R knockout mouse. Fig. S2 shows the in vivo bioactivity of in-
tradermally injected IL-12 and TNF. Fig. S3 shows the IL-23–dependent 
infl  ammatory cell infi  ltrate into mouse skin. Fig. S4 shows the IL-19 family 
receptor subunits in human psoriasis. Figs. S5–S7 show the gene deletion 
strategy for IL-20R2, IL-19, and IL-24 knockout mice, respectively. Fig. S8 
is a high magnifi  cation hematoxylin and eosin–stained section showing 
general features of an IL-23–mediated model. Fig. S9 shows a high mag-
nifi  cation hematoxylin and eosin–stained section illustrating an epidermal 
microabscess. Fig. S10 is a high magnifi  cation electron micrograph (EM) of 
spinous (bottom) and granular (top) layers (note presence of intercellular 
edema). Fig. S11 is a medium-high EM of junction between spinous and 
granular layers (note the presence of nuclear degeneration [condensed chro-
matin] in a granular cell [red arrow] vs. a more normal nucleus in a spinous 
cell [blue arrow]). Fig. S12 is a low magnifi  cation EM from a control animal 
illustrating the “normal” appearance of the epidermis (note that the granular 
layer is present, but not prominent, and there is little keratin). Fig. S13 is 
a high magnifi  cation EM from a control animal illustrating the “normal” 
appearance of the corneum (note the absence of nucleated keratinocytes 
and sparse keratohyalin granules). Table S1 is genotyping primers for analyz-
ing knockout mice. The online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20060244/DC1.
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